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factors include glaucoma and hypermetropia. Controversy exists to whether short axial length is a risk factor for retinal vein occlu-
sions. We report an extreme case that supports the latter hypothesis. A 33-year-old male presented with decreased visual acuity in
the left eye. He turned out to have nanophthalmos with hemiretinal vein occlusion and macular edema with unremarkable systemic
work up for retinal vein occlusion except for a glycated hemoglobin (HbA1c) level of 7%. To our knowledge this is the first case
report of hemiretinal vein occlusion in the setting of nanophthalmos and suggests that short axial length may be a risk factor for
retinal vein occlusion.
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Many risk factors have been linked to retinal vein occlu-
sions (RVOs) whether central, hemi or branch retinal vein
occlusion. Controversy exists to whether short axial length
is a risk factor for retinal vein occlusions. We report an
extreme case that may support the latter hypothesis.Case report
A 33-year-old male with no known medical illness pre-
sented to the emergency department with painless decrease
in vision in his left eye of 2 week duration. On examination
the best-corrected visual acuity was 20/40 in the right eye
(OD) and 20/300 in the left eye (OS). Refraction measured
+14.00  1.00  81 in OD and +14.00 + 1.00  104 in OS.
A +2 grade left afferent pupillary defect was present. The
intraocular pressure measured 20 mmHg in both eyes and
the anterior chamber angles were open bilaterally. The
patient had been maintained on Timolol eye drops twicedaily to both eyes for an unclear reason. The horizontal cor-
neal diameter measured 9.5 mm in both eyes and the axial
length was 16.35 mm and 16.28 mm in OD and OS respec-
tively thus making the diagnosis of nanophthalmos. Fundus
examination of the right eye was unremarkable except for
subtle thin retinal wrinkles in the papillomacular area
(Fig. 1a). The optic nerve in the right eye had a normal cup
to disk ratio. Spectral-domain optical coherence tomography
(SD-OCT) of the right eye showed a small dome-shaped pap-
illomacular fold and no macular edema (Fig. 1b). Fundus eval-
uation of the left eye showed flame-shaped hemorrhages in
the superior half of the retina with macular edema and optic
disk congestion (Fig. 2a). Fundus fluorescein angiography
(FFA) supported the diagnosis of hemiretinal vein occlusion
(HRVO) in this eye (Fig. 2b), and SD-OCT confirmed the pres-
ence of macular edema with significant neurosensory retinal
thickening primarily in the outer plexiform layer accompanied
by a few hyporeflective spaces (cysts) in the inner nuclear
layer (Fig. 3a). There was no evidence of retinal vasculitis in
either eye.e:
al.com
Figure 1. (a) Color photograph of the right fundus shows a thin papillomacular fold. (b) Macular spectral-domain optical coherence tomography of the
right eye shows a small dome-shaped papillomacular fold and no macular edema.
Figure 2. (a) Color photograph of the left fundus shows flame shaped hemorrhages in the superior half of the retina. (b) Fluorescein angiography shows
delayed venous filling.
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patient was performed and was normal except for a mild ele-
vation in the glycated hemoglobin (HbA1c) level of 7% sug-
gesting that the patient was diabetic, although he had
been unaware of it. These tests included a complete blood
count, PT/PTT, lipid profile, fasting blood sugar, glycated
hemoglobin, screening for sickle cell anemia, serum homo-
cysteine level, factor V Leiden mutation, protein C and S defi-
ciency, antithrombin deficiency, anticardiolipin antibodies
and anti-phospholipid antibodies.
Prior to proceeding with an intravitreal injection of an anti-
vascular endothelial growth factor agent (anti-VEGF), a glau-
coma service consultation corroborated that the anterior
chamber angle was open and no prophylactic iridotomy
was needed at the time. An intravitreal injection of bev-
acizumab 1.25 mg/0.05 ml was administered in the left eye
and 1 month later the visual acuity improved to 20/70. In
addition, the macular edema decreased dramatically making
evident the characteristic papillomacular fold (PMF) typically
seen on fundus examination and SD-OCT in eyes with poster-
ior microphthalmos and nanophthalmos (Fig. 3b), as well as
the typical features of the PMF previously described in theFigure 3. Macular spectral domain optical coherence tomograpliterature.1–3 These features had been mostly concealed by
the macular edema in the pre-treatment OCT and include:
(1) a dome-shaped, partial thickness retinal fold, sparing
the retinal pigment epithelium, photoreceptors, ellipsoid
zone, external limiting membrane and outer nuclear layer;
(2) preserved retinal stratification within and beyond the
PMF; (3) inner nuclear layer cysts and (4) an accompanying
increased posterior pole curvature (Figs. 1b and 3a and b).
Further follow up during the next 15 months showed
recurrence of the macular edema requiring 5 subsequent
injections of intravitreal anti-VEGF agents. At the last follow
up, at 15 months, visual acuity OS was 20/70, the intraretinal
hemorrhages and optic nerve congestion had subsided, no
new vessels had developed on the retina or optic disk or at
the anterior chamber angle, however narrowing of the ante-
rior chamber angle with an increase in the intraocular pres-
sure to 28 mmHg was observed in both eyes and the
patient was placed on topical antiglaucoma medications for
both eyes. On SD-OCT, the central macular thickness in OS
measured 550 microns. The classic features of the PMF were
again confounded by the macular edema, the inner nuclear
cysts, however, remained visible.hy of left eye before (a) and after (b) bevacizumab injection.
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Nanophthalmos is a developmental disorder of the eye in
which both the anterior and posterior segments are not
developed to full dimensions4 without major structural
abnormalities. Quantitatively, it is defined as an eye with vis-
ibly small anterior segment dimensions, namely a small cor-
neal diameter ranging between 9.5 and 11 mm, a shallow
anterior chamber depth, ranging from less than 1 mm to
2.7 mm, an increased crystalline lens to total eye volume
ratio,5 and an axial length of 20.5 mm or less,6 however in
most cases the axial length is typically less than 18.5 mm.7
Nanophthalmos is clinically distinguished from posterior
microphthalmos (PM), by the normal or subnormal dimen-
sions of the anterior segment in PM, although more recent
biometric and genetic studies support that PM and nanoph-
thalmos are part of a biometric spectrum instead of distinct
entities.7–9 Such extremely short eyes are prone to primary
angle closure glaucoma and uveal effusion. In addition, a
papillomacular fold (or winkles) is a characteristic finding in
nanophthalmos and PM.1–3 We report a case of HRVO asso-
ciated with nanophthalmos as an illustration of a potentially
new retinal complication that may be associated with nan-
ophthalmos. To our knowledge such an association has not
been previously reported.
Retinal vein occlusion (RVO) is the second most common
retinal vascular disorder after diabetic retinopathy and is con-
sidered to be an important cause of visual loss.10,11 Retinal
vein occlusions can be classified into central (CRVO), HRVO,
or branch retinal vein occlusions (BRVO). HRVO involves the
anterior part of a trunk of the central retinal vein.10 Many risk
factors have been linked to retinal vein occlusion whether
CRVO or BRVO. In the literature, RVO has been strongly
associated with hypertension, diabetes mellitus, retinal arte-
riolar abnormalities, hypertriglyceridemia and renal dysfunc-
tion.12,13 Several studies postulate that thrombophilic risk
factors may be more prevalent in younger patients especially
in a patient without other risk factors (hypertension, hyperlip-
idemia and diabetes mellitus).14 A meta-analysis of RVO
examined the prevalence of hyperhomocysteinemia, methyl-
enetetrahydrofolate reductase gene mutation, factor V Lei-
den mutation, protein C and S deficiency, antithrombin
deficiency, prothrombin gene mutation, anticardiolipin anti-
bodies, and lupus anticoagulant. Only hyperhomocystein-
emia and anticardiolipin antibodies had significant
effects.15,16 Glaucoma,17 short axial length and hypermetro-
pia have also been described as ocular risk factors for CRVO.
There is no consensus in the literature as to whether short
axial length is a real risk factor for RVO. Many authors believe
that short axial length increases the risk of RVO 18–21 while
others do not believe in such an association.22,23 All risk fac-
tors were negative in our patient except for significantly short
axial length and early diabetes. The case reported herein
supports a potential role for a short axial length in RVO
and further observation of such association may help in
establishing stronger evidence.
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